| Literature DB >> 10811470 |
N Yen1, C G Ioannides, K Xu, S G Swisher, D D Lawrence, B L Kemp, A K El-Naggar, R J Cristiano, B Fang, B S Glisson, W K Hong, F R Khuri, J M Kurie, J J Lee, J S Lee, J A Merritt, T Mukhopadhyay, J C Nesbitt, D Nguyen, R Perez-Soler, K M Pisters, J B Putnam, D S Schrump, D M Shin, G L Walsh, J A Roth.
Abstract
The immune responses of 10 patients with advanced non-small cell lung cancer receiving monthly intratumoral injections of a recombinant adenovirus containing human wild-type p53 (Ad-p53) to adenovirus and transgene antigens were studied. The predominate cellular and humoral immune responses as measured by lymphocyte proliferation and neutralizing antibody (Ab) formation were to adenovirus serotype 5 vector antigens, with increased responses in posttreatment samples. Consistent alterations in posttreatment cellular and humoral immune responses to p53 epitopes were not observed, and cytotoxic Abs to human lung cancer cells were not generated. Patients in this study had evidence of an antitumoral effect of this treatment with prolonged tumor stability or regression; however, neither Abs to p53 protein nor increased lymphocyte proliferative responses to wild-type or mutant p53 peptides have been consistently detected.Entities:
Mesh：
Substances：
Year: 2000 PMID： 10811470 DOI： 10.1038/sj.cgt.7700138
Source DB: PubMed Journal: Cancer Gene Ther ISSN： 0929-1903 Impact factor: 5.987